Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2024-02-08 00:00:00 ET · period of report 2024-02-07 · accession 0001968202-24-000056 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-02-08 | 2024-02-07 | REGN | STAHL NEIL | EVP Research, Development | S - Sale | $950.35 | -8,037 | 54.3K | -13% | -$7.64M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-07 | S | D | 100 | $947.34 | 59,956 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-07 | S | D | 1,894 | $948.69 | 58,062 | D | — | — | (F1) Represents volume-weighted average price of sales of 1,894 shares of Company stock on February 7, 2024 at prices ranging from $948.19 to $948.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2024 at each separate price. |
| 3 | Common | Common Stock | 2024-02-07 | S | D | 601 | $949.45 | 57,461 | D | — | — | (F2) Represents volume-weighted average price of sales of 601 shares of Company stock on February 7, 2024 at prices ranging from $949.22 to $949.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2024 at each separate price. |
| 4 | Common | Common Stock | 2024-02-07 | S | D | 19 | $953.00 | 52,019 | D | — | — | |
| 5 | Common | Common Stock | 2024-02-07 | S | D | 1,237 | $951.49 | 53,097 | D | — | — | (F4) Represents volume-weighted average price of sales of 1,237 shares of Company stock on February 7, 2024 at prices ranging from $951.00 to $951.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2024 at each separate price. |
| 6 | Common | Common Stock | 2024-02-07 | S | D | 1,059 | $952.49 | 52,038 | D | — | — | (F5) Represents volume-weighted average price of sales of 1,059 shares of Company stock on February 7, 2024 at prices ranging from $952.03 to $952.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2024 at each separate price. |
| 7 | Common | Common Stock | 2024-02-07 | S | D | 3,127 | $950.43 | 54,334 | D | — | — | (F3) Represents volume-weighted average price of sales of 3,127 shares of Company stock on February 7, 2024 at prices ranging from $950.00 to $950.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 7, 2024 at each separate price. |